Clinical

Dataset Information

0

Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer


ABSTRACT: The aim of this study is to determine the efficacy of combining the histone deacetylase (HDAC) inhibitor sodium valproate (VPA) with anti-EGFR monoclonal antibody (panitumumab or cetuximab) maintenance in the first-line treatment of patients with RAS wild type metastatic CRC.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms,Valproic Acid

PROVIDER: 5791 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2265349 | ecrin-mdr-crc
| S-EPMC7922143 | biostudies-literature
| S-EPMC7072611 | biostudies-literature
| S-EPMC6375935 | biostudies-literature
2024-05-24 | PXD039836 | Pride
| S-EPMC6831181 | biostudies-literature
| S-EPMC6886544 | biostudies-literature
| 2322657 | ecrin-mdr-crc
| S-EPMC4685498 | biostudies-literature
| S-EPMC5760518 | biostudies-literature